Replies to post #234193 on Biotech Values

[DewDiligence]

Xeomin and Botox are both FDA-approved for upper-limb spasticity; however, Botox’s FDA label shows a higher rate of respiratory infections, which might be a particular concern during the COVID-19 pandemic.